Cooper Companies (COO) Given a $265.00 Price Target at Oppenheimer

Share on StockTwits

Oppenheimer set a $265.00 price target on Cooper Companies (NYSE:COO) in a report released on Friday, June 8th. The firm currently has a hold rating on the medical device company’s stock.

Other equities analysts also recently issued reports about the company. Zacks Investment Research upgraded Cooper Companies from a hold rating to a buy rating and set a $265.00 price objective for the company in a research report on Tuesday, May 22nd. Jefferies Financial Group restated a buy rating and set a $285.00 price objective on shares of Cooper Companies in a research report on Friday, March 9th. TheStreet downgraded Cooper Companies from a b rating to a c rating in a report on Thursday, March 8th. Stephens reiterated a hold rating and issued a $270.00 target price on shares of Cooper Companies in a report on Friday, March 9th. Finally, Cleveland Research downgraded Cooper Companies from a buy rating to a hold rating in a report on Friday, February 9th. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $265.36.

Shares of Cooper Companies opened at $237.23 on Friday, according to MarketBeat.com. Cooper Companies has a 1 year low of $216.47 and a 1 year high of $260.26. The company has a quick ratio of 1.67, a current ratio of 2.76 and a debt-to-equity ratio of 0.77. The stock has a market cap of $11.49 billion, a PE ratio of 24.46, a P/E/G ratio of 1.84 and a beta of 0.61.

Cooper Companies (NYSE:COO) last issued its quarterly earnings data on Thursday, June 7th. The medical device company reported $2.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.02. Cooper Companies had a return on equity of 17.14% and a net margin of 5.58%. The company had revenue of $631.30 million during the quarter, compared to the consensus estimate of $627.49 million. During the same period last year, the company earned $2.50 earnings per share. The firm’s revenue was up 20.8% compared to the same quarter last year. research analysts anticipate that Cooper Companies will post 11.81 EPS for the current fiscal year.

In other Cooper Companies news, Director Allan E. Rubenstein sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $235.13, for a total value of $235,130.00. Following the completion of the sale, the director now owns 4,568 shares of the company’s stock, valued at $1,074,073.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael Kalkstein sold 1,715 shares of the firm’s stock in a transaction that occurred on Wednesday, April 11th. The shares were sold at an average price of $221.66, for a total value of $380,146.90. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Schroder Investment Management Group grew its stake in Cooper Companies by 3.4% in the fourth quarter. Schroder Investment Management Group now owns 414,626 shares of the medical device company’s stock valued at $90,339,000 after acquiring an additional 13,442 shares during the period. Jane Street Group LLC grew its stake in Cooper Companies by 1,061.5% in the fourth quarter. Jane Street Group LLC now owns 11,336 shares of the medical device company’s stock valued at $2,470,000 after acquiring an additional 10,360 shares during the period. Raymond James & Associates grew its stake in Cooper Companies by 62.9% in the fourth quarter. Raymond James & Associates now owns 35,809 shares of the medical device company’s stock valued at $7,802,000 after acquiring an additional 13,824 shares during the period. Wells Fargo & Company MN grew its stake in Cooper Companies by 41.5% in the fourth quarter. Wells Fargo & Company MN now owns 250,479 shares of the medical device company’s stock valued at $54,574,000 after acquiring an additional 73,427 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in Cooper Companies by 9.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 10,113 shares of the medical device company’s stock valued at $2,205,000 after acquiring an additional 850 shares during the period. 96.83% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply